Search

Your search keyword '"Cholangitis, Sclerosing drug therapy"' showing total 623 results

Search Constraints

Start Over You searched for: Descriptor "Cholangitis, Sclerosing drug therapy" Remove constraint Descriptor: "Cholangitis, Sclerosing drug therapy"
623 results on '"Cholangitis, Sclerosing drug therapy"'

Search Results

1. Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.

2. ROS-responsive nanoparticle delivery of obeticholic acid mitigate primary sclerosing cholangitis.

3. An 'Adaptive Treatment Strategy' for Oral Vancomycin in Patients with the Orphan Disease Primary Sclerosing Cholangitis.

4. Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis.

5. Elafibranor: First Approval.

6. Idiopathic hyalinizing fibrosclerosis: A systemic steroid-resistant condition distinct from IgG4-related disease.

7. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments.

8. Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.

9. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.

10. Pneumocystis jirovecii Pneumonia Complicating Use of Upadacitinib in a Patient With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Case Report.

11. Blockade of forkhead box protein O1 signaling alleviates primary sclerosing cholangitis-induced sarcopenia in mice model.

12. Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.

13. Network proximity analysis as a theoretical model for identifying potential novel therapies in primary sclerosing cholangitis.

14. Berberine ameliorates the progression of primary sclerosing cholangitis by activating farnesoid X receptor.

15. Patient-focused drug development in primary sclerosing cholangitis: Insights on patient priorities and involvement in clinical trials.

16. Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?

17. Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.

18. Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis.

19. Letter to editor: effects of vancomycin in primary sclerosing cholangitis with and without inflammatory bowel disease.

20. Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.

21. An atypical case of isolated immunoglobulin G4-related sclerosing cholangitis with a cholangiogram resembling primary sclerosing cholangitis.

22. Novel preclinical developments of the primary sclerosing cholangitis treatment landscape.

23. A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis.

24. Treatment of Primary Sclerosing Cholangitis Including Transplantation.

25. Beta-lapachone ameliorates the progression of primary sclerosing cholangitis pathogenesis in rodent models.

26. Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis.

27. Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center.

28. CsHscB Derived from a Liver Fluke Clonorchis sinensis Ameliorates Cholestatic Hepatic Fibrosis in a Mouse Model of Sclerosing Cholangitis.

29. Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis.

30. Significant CA 19-9 elevation in IgG4-related autoimmune pancreatitis - A diagnostic dilemma.

33. [Translated article] Oral vancomycin in a pediatric patient with primary sclerosing cholangitis and inflammatory bowel disease.

34. Pembrolizumab-induced immune-related sclerosing cholangitis.

35. Eosinophilic Granulomatosis with Polyangiitis Presenting as Steroid-Responsive Sclerosing Cholangitis and Cholecystitis: A Rare Case Report.

37. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks.

38. Recent Advances in the Management of Primary Sclerosing Cholangitis.

39. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.

41. Cholestatic Pruritus Treatments in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Systematic Literature Review.

42. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.

44. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.

45. Ulcerative colitis complicated by primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome: a case report and literature review.

46. Bile Duct Colonization With Enterococcus sp. Associates With Disease Progression in Primary Sclerosing Cholangitis.

47. Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.

48. Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: A multicenter cohort study.

49. Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.

Catalog

Books, media, physical & digital resources